Wegovy Weight Loss in Newport Beach

When the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021, it marked the most significant advance in obesity pharmacotherapy in decades. Two years later, the SELECT trial confirmed that semaglutide reduces the risk of serious cardiovascular events by 20 percent in overweight and obese adults — making Wegovy the only weight loss medication with proven cardiovascular mortality benefit. At Adonis Saremi, MD, Newport Beach patients access a physician-supervised Wegovy program built to fully leverage this medication’s extraordinary clinical profile.

What Makes Wegovy Clinically Different

Wegovy delivers semaglutide 2.4 mg via once-weekly subcutaneous injection — a dose specifically optimized for chronic weight management, higher than the 0.5 to 2 mg range used for diabetes. The STEP 1 trial showed 14.9 percent average weight loss versus 2.4 percent on placebo over 68 weeks. STEP 4 demonstrated that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their weight within a year — underscoring the importance of physician-planned maintenance.

The Evidence Behind Wegovy

• STEP 1 (2021) — 14.9 percent average weight loss versus 2.4 percent placebo over 68 weeks in non-diabetic patients
• SELECT trial (2023) — 20 percent reduction in major adverse cardiovascular events in overweight adults without diabetes
• STEP 4 — patients who stopped semaglutide at 20 weeks regained approximately 11.6 of 17.3 lost pounds within a year
• STEP 5 — 15.2 percent average weight loss sustained over 104 weeks, confirming long-term efficacy

Is Wegovy the Right Program for You in Newport Beach?

• Adults in Newport Beach with a BMI of 30-plus, or 27-plus with hypertension, dyslipidemia, or another qualifying condition, who want FDA-approved chronic weight management therapy
• Patients who have tried dietary and lifestyle interventions seriously without adequate results — ready for a pharmaceutical approach backed by landmark clinical evidence
• Individuals with elevated cardiovascular risk who want a weight loss medication with a proven mortality benefit — the SELECT trial distinction is clinically meaningful
• Those who want a Wegovy program actively managed with proper titration, lab monitoring, and dietary integration — not just a prescription and a monthly refill
• Patients across Newport Beach and Orange County looking for a physician who can contextualize Wegovy within their full health picture.

The SELECT Trial Changes the Clinical Calculus

For Newport Beach patients with cardiovascular risk factors, Wegovy is not simply a weight loss medication — it is a cardiovascular intervention with FDA backing. Dr. Adonis Saremi’s Internal Medicine board certification means he evaluates this dimension with the clinical depth it warrants.

Start your Wegovy program in Newport Beach. Call (619) 736-1748 or book your consultation online today.

Frequently Asked Questions

How does Wegovy differ from Ozempic?

Both contain semaglutide, but Wegovy uses the higher 2.4 mg dose specifically approved for chronic weight management. Ozempic is approved for type 2 diabetes at doses up to 2 mg.

What results can I realistically expect?

The STEP trials showed average weight loss of 14.9 to 17.4 percent across patient populations. Individual outcomes depend on adherence, lifestyle factors, and baseline health status.

What happens if I stop taking Wegovy?

Weight regain is the expected clinical outcome without a transition strategy. Our program builds a structured maintenance phase into every patient’s plan from day one.